Suven Life Sciences Ltd

Pursuant to Regulation 82(4) of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirement) Regulations 2018 and Regulation 32 (6) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we are enclosing herewith the Monitoring Agency Report with respect to utilization of proceeds of the Rights Issue of the Company for the quarter ended on December 31 2022 issued by CRISIL Ratings Limited Monitoring Agency.